Effect of age at vaccination on the measles vaccine effectiveness and immunogenicity: systematic review and meta-analysis
Open Access
- 29 March 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in BMC Infectious Diseases
- Vol. 20 (1), 1-18
- https://doi.org/10.1186/s12879-020-4870-x
Abstract
The objectives of this review were to evaluate the effect of age at administration of the first dose of a measles-containing vaccine (MCV1) on protection against measles and on antibody response after one- and two-dose measles vaccinations. We conducted a systematic review of the PubMed/MEDLINE, Embase, Web of Science and Cochrane databases (1964–2017) to identify observational studies estimating vaccine effectiveness and/or measles attack rates by age at first vaccination as well as experimental studies comparing seroconversion by age at first vaccination. Random effect models were used to pool measles risk ratios (RR), measles odds ratios (OR) and seroconversion RR of MCV1 administered at < 9, 9–11 or ≥ 15 months compared with 12 or 12–14 months of age. We included 41 and 67 studies in the measles protection and immunogenicity analyses. Older age at MCV1, from 6 to ≥15 months, improved antibody response and measles protection among one-dose recipients. Pooled measles RR ranged from 3.56 (95%CI: 1.28, 9.88) for MCV1 at < 9 months to 0.48 (95%CI: 0.36, 0.63) for MCV1 at ≥15 months, both compared to 12–14 months. Pooled seroconversion RR ranged from 0.93 (95%CI: 0.90, 0.96) for MCV1 at 9–11 months to 1.03 (95%CI: 1.00, 1.06) for MCV1 at ≥15 months, both compared to 12 months. After a second dose, serological studies reported high seropositivity regardless of age at administration of MCV1 while epidemiological data based on few studies suggested lower protection with earlier age at MCV1. Earlier age at MCV1 decreases measles protection and immunogenicity after one dose and might still have an impact on vaccine failures after two doses of measles vaccine. While two-dose vaccination coverage is most critical to interrupt measles transmission, older age at first vaccination may be necessary to keep the high level of population immunity needed to maintain it.Keywords
This publication has 154 references indexed in Scilit:
- Measles Elimination Efforts and 2008–2011 Outbreak, FranceEmerging Infectious Diseases, 2013
- Sero-epidemiology of measles-specific IgG antibodies and predictive factors for low or missing titres in a German population-based cross-sectional study in children and adolescents (KiGGS)Vaccine, 2011
- Kinetics of Decline of Maternal Measles Virus-Neutralizing Antibodies in Sera of Infants in France in 2006Clinical and Vaccine Immunology, 2008
- Humoral and Cell‐Mediated Immune Responses to an Early 2‐Dose Measles Vaccination Regimen in the United StatesThe Journal of Infectious Diseases, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- Comparison of gelatin particle agglutination and hemagglutination inhibition tests for measles seroepidemiology studiesArchiv für die gesamte Virusforschung, 1997
- The Effect of Edmonston-Zagreb and Schwarz Measles Vaccines on Immune Responses in InfantsThe Journal of Infectious Diseases, 1996
- Immunization of Six-Month-Old Infants with Different Doses of Edmonston–Zagreb and Schwarz Measles VaccinesThe New England Journal of Medicine, 1990
- Response to Measles Vaccine in Haitian Infants 6 to 12 Months OldThe New England Journal of Medicine, 1985
- Additional evidence against measles vaccine administration to infants less than 12 months of age: Altered immune response following active/passive immunizationThe Journal of Pediatrics, 1979